COMMUNIQUÉS West-GlobeNewswire

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
11/03/2026
Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturing All activities other than long-term stability testing planned to be complete in Q3 [...]
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
11/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea
11/03/2026
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure- [...]
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Throughout February this year, smart wellness innovator UREVO launched its new campaign, " Train Hard, Recover Smart ," encouraging sports enthusiasts worldwide to take a [...]
La Commission européenne approuve AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2
11/03/2026
Le traitement par niraparib et acétate d’abiratérone démontre un retard cliniquement significatif dans la progression de la maladie, réduisant de près de moitié le risque de progression ou de décès, avec une tendance [...]
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
11/03/2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- [...]
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
11/03/2026
Company Reports Record Revenue and Profitability for Full-Year 2025 REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company [...]
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
11/03/2026
– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from [...]
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
11/03/2026
Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage Full Year 2025 Revenue [...]
NurExone Announces Corporate Updates
11/03/2026
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ( [...]
Community Care Cooperative (C3) Earns $10.2 Million in Shared Savings Through Medicare Shared Savings Program (MSSP) Track A for Performance Year 2024
11/03/2026
BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Community Care Cooperative (C3), the largest and most successful non-profit, FQHC-governed ACO in the country, announced today that it achieved $10.2 million in shared savings [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
11/03/2026
CRANFORD, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth
11/03/2026
Fully Funded Growth Strategy Supports Aircraft Fleet Expansion Providing Capacity to Service Current Demand in New Regions FORT MILL, S.C., March 11, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: [...]
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
11/03/2026
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, [...]
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03/2026
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a [...]
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
11/03/2026
ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” [...]
Annual General Meeting 2026 – GN Store Nord A/S
11/03/2026
Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 16, 2026, as set out below. The report by the Board of Directors was [...]
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
11/03/2026
Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers U.S. naloxone market totals $141M with 9.4 million [...]
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
11/03/2026
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s disease First person has been dosed [...]

Pages